Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01727089 · ClinicalTrials.gov registry record · Phase 2
Bevacizumab With or Without TRC105 in Treating Patients With Metastatic Kidney Cancer
A Phase 2 study, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 2
- Development phase
- 59
- Enrollment target
NCT01727089: Completed Phase 2 study, sponsored by National Cancer Institute (NCI).
NCT01727089 is a Phase 2 study that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 59 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01727089, a Phase 2 study, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 59 participants
- Enrollment target
Study Summary
This randomized phase II trial studies how well bevacizumab with or without anti-endoglin monoclonal antibody TRC105 (TRC105) works in treating patients with kidney cancer that has spread to other parts of the body (metastatic). Monoclonal antibodies, such as bevacizumab and anti-endoglin monoclonal antibody TRC105, may block tumor growth in different ways by targeting certain cells.
Interventions
- OTHER Laboratory Biomarker Analysis
- BIOLOGICAL Bevacizumab
- OTHER Pharmacological Study
- BIOLOGICAL Anti-Endoglin Chimeric Monoclonal Antibody TRC105
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 59 participants |
| Start Date | 2012-11-01 |
| Est. Completion | 2017-08-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01727089
The ClinicalTrials.gov registry entry for NCT01727089 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 59 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Laboratory Biomarker Analysis is the first listed.
NCT01727089 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01727089 about?
NCT01727089 is a clinical study titled "Bevacizumab With or Without TRC105 in Treating Patients With Metastatic Kidney Cancer". This randomized phase II trial studies how well bevacizumab with or without anti-endoglin monoclonal antibody TRC105 (TRC105) works in treating patients with kidney cancer that has spread to other parts of the body (metastatic). Monoclonal antibodies, such as bevacizumab and anti-endoglin monoclonal...
What is the current status of trial NCT01727089?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 59 participants. The study started on 2012-11-01. Estimated completion is 2017-08-08.
What interventions are being tested in trial NCT01727089?
The interventions under investigation include: Laboratory Biomarker Analysis (OTHER), Bevacizumab (BIOLOGICAL), Pharmacological Study (OTHER), Anti-Endoglin Chimeric Monoclonal Antibody TRC105 (BIOLOGICAL).
Who is sponsoring clinical trial NCT01727089?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.